[Therapy of bone metastases with radium-223. German guidelines].

Pöppel, Thorsten D; Andreeff, Michael; Becherer, Alexander; Bockisch, Andreas; Fricke, Eva; Geworski, Lilli; Heinzel, Alexander; Krause, Bernd J; Krause, Thomas Michael; Mitterhauser, Markus; Scheidhauer, Klemens; Schenck, Marcus; Sonnenschein, Wilfried; Gabriel, Michael (2016). [Therapy of bone metastases with radium-223. German guidelines]. Nuklearmedizin / Nuclear medicine, 55(5), pp. 177-186. Schattauer 10.3413/Nukmed-2016050001

[img] Text
Therapy of bone metastases with radium-223.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (213kB)

This document describes the guideline for therapy of bone metastases with radium-223 ((223)Ra) published by the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften in Germany (AWMF) under the auspices of the Deutsche Gesellschaft für Nuklearmedizin (DGN), Östereichische Gesellschaft für Nuklearmedizin (OGN), and Schweizerische Gesellschaft für Nuklearmedizin (SGNM). This guidance is based on an interdisciplinary consensus. These recommendations are a prerequisite for the quality management in the treatment of patients with bone metastases from prostate cancer using (223)Ra. They are aimed at guiding nuclear medicine specialists in selecting candidates to receive therapy and to deliver the treatment in a safe and effective manner. The document contains background information and definitions. It covers the rationale, indications and contraindications for therapy with (223)Ra. Essential topics are the requirements for institutions performing the therapy, which patient data have to be available prior to performance of therapy, and how treatment has to be carried out technically and organisationally. Moreover, essential elements of follow-up and aftercare are specified. As a matter of principle, the treatment inclusive aftercare has to be realised in close cooperation with the involved medical disciplines.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Krause, Thomas Michael

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0029-5566

Publisher:

Schattauer

Language:

German

Submitter:

Franziska Nicoletti

Date Deposited:

07 Feb 2017 11:34

Last Modified:

05 Dec 2022 15:02

Publisher DOI:

10.3413/Nukmed-2016050001

PubMed ID:

27417067

Uncontrolled Keywords:

Radionuclide therapy; Radium-223; alpha emitter; bone metastases; prostate cancer

BORIS DOI:

10.7892/boris.94284

URI:

https://boris.unibe.ch/id/eprint/94284

Actions (login required)

Edit item Edit item
Provide Feedback